Merck : MRK

All Merck Articles

1067 Articles

Jon C. Ogg | May 3, 2014 at 8:35 AM EDT

The Four Best DJIA Stocks of 2014 So Far, and Looking Forward

This past week brought yet another swing taking the Dow Jones Industrial Average to within 30 points or so of…

Paul Ausick | May 2, 2014 at 11:20 AM EDT

Can Endocyte Survive Its Cancer Drug Implosion?

Endocyte and Merck have terminated their joint late-stage study of an ovarian cancer treatment after the trials failed to show…

Jon C. Ogg | Apr 30, 2014 at 8:30 AM EDT

Top Analyst Upgrades and Downgrades: Coach, Merck, Netflix, Sprint, Twitter and More

These are the top analyst upgrades, downgrades and initiations from Wall Street on Wednesday, April 30, 2014. They include ARM…

Paul Ausick | Apr 29, 2014 at 4:01 PM EDT

The 4 Stocks That Kept Markets Higher

thinkstockApril 29, 2014: Markets opened higher on Tuesday getting a boost from energy and biotech stocks right at the start…

Paul Ausick | Apr 29, 2014 at 7:45 AM EDT

Merck Earnings Mixed as Drug Sales Slow

Merck & Co. reported mixed first-quarter 2014 results before markets opened Tuesday morning. The loss of market exclusivity continues to…

cgblaine22 | Apr 26, 2014 at 8:30 AM EDT

Biotech: The Poster Child for Market Volatility in 2014

The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5.…

Jon C. Ogg | Apr 23, 2014 at 8:50 AM EDT

UBS Top Stocks to Buy Working for Cancer Cures

In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are…

Paul Ausick | Apr 15, 2014 at 8:30 AM EDT

Johnson & Johnson Earnings Point to New 52-Week High

Johnson & Johnson reported better-than-expected first-quarter results before markets opened Tuesday morning. And the company boosted its earnings guidance for…

Jon C. Ogg | Apr 10, 2014 at 11:33 AM EDT

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

Gilead Sciences may have been largely responsible for the drop in biotech stocks after politicians went after its drug costs,…

Paul Ausick | Apr 9, 2014 at 4:01 PM EDT

The 4 Stocks That Inspired The Bounce

thinkstockApril 9, 2014: Markets opened higher on Wednesday and then got a jolt higher following the afternoon release of the…

Paul Ausick | Mar 26, 2014 at 9:05 AM EDT

Telecoms Liven Up Short Interest in Big Dividend Stocks

ThinkstockThe short interest data for the first two weeks of March is out, and the results among the top high-yield…

Trey Thoelcke | Mar 26, 2014 at 8:45 AM EDT

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large…

Paul Ausick | Mar 25, 2014 at 4:01 PM EDT

The 4 Stocks That Charged the Market Higher

thinkstockMarch 25, 2014: Markets opened higher on Tuesday but dipped sharply in the late morning on weakness in consumer discretionary,…

Paul Ausick | Mar 24, 2014 at 4:01 PM EDT

The 4 Stocks That Pushed Stocks Lower on Monday

thinkstockMarch 24, 2014: Markets opened slightly higher on Monday but soon took a turn south and spent most of the…

Paul Ausick | Mar 21, 2014 at 4:01 PM EDT

The 5 Stocks That Sank Markets on Friday

thinkstockMarch 21, 2014: Markets opened higher on Friday but the Nasdaq sank quickly, bounced for a while, and finally settled…

1 … 47 48 49 50 51 … 72

Merck : MRK

All Merck Articles

The Four Best DJIA Stocks of 2014 So Far, and Looking Forward

Can Endocyte Survive Its Cancer Drug Implosion?

Top Analyst Upgrades and Downgrades: Coach, Merck, Netflix, Sprint, Twitter and More

The 4 Stocks That Kept Markets Higher

Merck Earnings Mixed as Drug Sales Slow

Biotech: The Poster Child for Market Volatility in 2014

UBS Top Stocks to Buy Working for Cancer Cures

Johnson & Johnson Earnings Point to New 52-Week High

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

The 4 Stocks That Inspired The Bounce

Telecoms Liven Up Short Interest in Big Dividend Stocks

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

The 4 Stocks That Charged the Market Higher

The 4 Stocks That Pushed Stocks Lower on Monday

The 5 Stocks That Sank Markets on Friday

A Couple With $3.5 Million Discovers State Estate Taxes Could Cost Their Kids Six Figures

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

SMH Has Crushed the S&P 500 by 2,041% Over a Decade, But Recent 42% Rally Signals Dangerous Valuations

A Couple With $3.5 Million Discovers State Estate Taxes Could Cost Their Kids Six Figures

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month

A Couple With $3.5 Million Discovers State Estate Taxes Could Cost Their Kids Six Figures

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

Merck : MRK

All Merck Articles

The Four Best DJIA Stocks of 2014 So Far, and Looking Forward

Can Endocyte Survive Its Cancer Drug Implosion?

Top Analyst Upgrades and Downgrades: Coach, Merck, Netflix, Sprint, Twitter and More

The 4 Stocks That Kept Markets Higher

Merck Earnings Mixed as Drug Sales Slow

Biotech: The Poster Child for Market Volatility in 2014

UBS Top Stocks to Buy Working for Cancer Cures

Johnson & Johnson Earnings Point to New 52-Week High

Gilead Risks Beyond Just Merck: Serious Chart Violation Watch

The 4 Stocks That Inspired The Bounce

Telecoms Liven Up Short Interest in Big Dividend Stocks

J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now

The 4 Stocks That Charged the Market Higher

The 4 Stocks That Pushed Stocks Lower on Monday

The 5 Stocks That Sank Markets on Friday

A Couple With $3.5 Million Discovers State Estate Taxes Could Cost Their Kids Six Figures

MISL Investors: Watch the FY27 Budget Bill Before the Next Rally

SMH Has Crushed the S&P 500 by 2,041% Over a Decade, But Recent 42% Rally Signals Dangerous Valuations

Featured Reads

A Couple With $3.5 Million Discovers State Estate Taxes Could Cost Their Kids Six Figures

A 71-Year-Old's $850,000 Home Is Her Biggest Retirement Asset. Downsizing Could Add $2,250 a Month